Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages

  Burney, Basil O ^a   Hayes, Teresa G ^a   Smiechowska, Joanna ^a   Cardwell, Gina ^a   Papusha, Victor ^a   Bhargava, Peeyush ^a   Konda, Bhavana ^b   Auchus, Richard J ^c   Garcia, Jose M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINO TERMINAL TELOPEPTIDE; C REACTIVE PROTEIN; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; OSTEOCALCIN; PACLITAXEL; PLATINUM COMPLEX; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; BODY FAT; BONE TURNOVER; CACHEXIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; GRIP STRENGTH; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; KARNOFSKY PERFORMANCE STATUS; LEAN BODY WEIGHT; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PENIS ERECTION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL FUNCTION; SYMPTOM; TESTOSTERONE BLOOD LEVEL; UROGENITAL TRACT CANCER;

ADIPOSITY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CACHEXIA; CROSS-SECTIONAL STUDIES; FATIGUE; HAND STRENGTH; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MUSCLE STRENGTH; NEOPLASMS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE;

EID: 84860734158     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2387     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E 2010 Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Chatterjee R, Kottaridis PD, McGarrigle HH, Linch DC 2002 Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dosetherapy for haematological malignancies. Bone Marrow Transplant 29:607-610
3. Maltoni M, Nanni O, Pirovano M, Scarpi E, Indelli M, Martini C, Monti M, Arnoldi E, Piva L, Ravaioli A, Cruciani G, Labianca R, Amadori D 1999 Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage 17:240-247
4. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR 2004 Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 61:162-167
5. Haring R, Völzke H, Steveling A, Krebs A, Felix SB, Schöfl C, Dörr M, Nauck M, Wallaschofski H 2010 Low serum testosterone levels are associated with increased riskof mortality in a population-based cohort of men aged 20-79. Eur Heart J 31:1494-1501
6. Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, Cunningham GR 2006 Hypogonadism in male patients with cancer. Cancer 106:2583-2591
7. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E 2004 Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100:851-858
8. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, Smith RG, Cunningham GR, Marcelli M 2005 Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90:2920-2926
9. Tisdale MJ 2002 Cachexia in cancer patients. Nat Rev Cancer 2:862-871
10. Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO 2002 Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293:560-565
11. Tsigos C, Papanicolaou DA, Kyrou I, Raptis SA, Chrousos GP 1999 Dose-dependent effects of recombinant human interleukin-6 on the pituitary-testicular axis. J Interferon Cytokine Res 19:1271-1276
12. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K 1991 The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6-9
13. Heedman PA, Strang P 2001 Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res 21:4077-4082
14. Cella DF, Von Roenn J, Lloyd S, Browder HP 1995 The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients' subjective response to treatment for anorexia/cachexia. Qual Life Res 4:221-231
15. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS 2004 Longterm testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89:2085-2098
16. Lee KK, Berman N, Alexander GM, Hull L, Swerdloff RS, Wang C 2003 A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl 24:688-698
17. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A 1997 The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822-830
18. Beck AT, Ward J 1972 Beck depression inventory. In: Beck AT, ed. Depression: causes and treatment. Philadelphia, PA: University of Pennsylvania Press
19. Walker MS, Zona DM, Fisher EB 2006 Depressive symptoms after lung cancer surgery: their relation to coping style and social support. Psychooncology 15:684-693
20. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL 2005 Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502-1510
21. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666-3672
22. Egleston BL, Chandler DW, Dorgan JF 2010 Validity of estimating non-sex hormone-binding globulin bound testosterone and oestradiol from total hormone measurements in boys and girls. Ann Clin Biochem 47:233-241
23. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry 3rd HM 2000 Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49:1239-1242
24. Reuben DB, Mor V, Hiris J 1988 Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 148:1586-1591
25. Gale CR, Martyn CN, Cooper C, Sayer AA 2007 Grip strength, body composition, and mortality. Int J Epidemiol 36:228-235
26. Sattler F, Bhasin S, He J, Chou CP, Castaneda-Sceppa C, Yarasheski K, Binder E, Schroeder ET, Kawakubo M, Zhang A, Roubenoff R, Azen S 2011 Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. J Gerontol A Biol Sci Med Sci 66:122-129
27. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, De Paoli AM, Karalis A, Mantzoros CS 2004 Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351:987-997
28. Smiechowska J, Utech A, Taffet G, Hayes T, Marcelli M, Garcia JM 2010 Adipokines in patients with cancer anorexia and cachexia. J Investig Med 58:554-559
29. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR 2001 Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724-731
30. Todd BD 1988 Pancreatic carcinoma and low serum testosterone; a correlation secondary to cancer cachexia? Eur J Surg Oncol 14:199-202
31. Svartberg J, Midtby M, Bønaa KH, Sundsfjord J, Joakimsen RM, Jorde R 2003 The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromso Study. Eur J Endocrinol 149:145-152
32. Fleishman SB, Khan H, Homel P, Suhail MF, Strebel-Amrhein R, Mohammad F, Mahajan D, Rosenwald V, Guarino MJ, Mirzoyev T, Wozniak TF, Suppiah K 2010 Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. J Clin Oncol 28:5054-5060
33. Gerl A, Mühlbayer D, Hansmann G, Mraz W, Hiddemann W 2001 The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 91:1297-1303
34. Iglesias P, Carrero JJ, Díez JJ 2012 Gonadaldys function in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol 25:31-42
35. Misra M, Klibanski A 2010 Neuroendocrine consequences of anorexia nervosa in adolescents. Endocr Dev 17:197-214
36. Celentano V, Fabbrocile G, Luglio G, Antonelli G, Tarquini R, Bucci L 2010 Prospective study of sexual dysfunction in men with rectal cancer: feasibility and results of nerve sparing surgery. Int J Colorectal Dis 25:1441-1445
37. Ploussard G, de la Taille A, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC, Salomon L 2011 Prospective evaluation of combined oncological and functional outcomes after laparoscopic radical prostatectomy: trifecta rate of achieving continence, potency and cancer control at 2 years. BJU Int 107:274-279
38. Hanada T, Toshinai K, Kajimura N, Nara-Ashizawa N, Tsukada T, Hayashi Y, Osuye K, Kangawa K, Matsukura S, Nakazato M 2003 Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 301:275-279
39. Del Fabbro E, Hui D, Nooruddin ZI, Dalal S, Dev R, Freer G, Roberts L, Palmer JL, Bruera E 2010 Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage 39:1016-1024
40. Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E, Dessì M, Panzone F 2010 Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med 88:85-92
41. Li CT, Marek M, Guclu SZ, Kim Y, Meshref M, Qin S, Kadziola Z, Krejcy K, Altug S 2011 Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma. J Cancer 2:52-61
42. Kim ST, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ 2010 Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment. Oncology 79:78-84
43. Vigano A, Piccioni M, Trutschnigg B, Hornby L, Chaudhury P, Kilgour R 2010 Male hypogonadism associated with advanced cancer: a systematic review. Lancet Oncol 11:679-684
44. Mantovani G, Macciò A, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Madeddu C, Dessì A 2000 Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 78:554-561
45. Baker KS, Ness KK, Weisdorf D, Francisco L, Sun CL, Forman S, Bhatia S 2010 Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Leukemia 24:2039-2047
46. Langley R, Price P, Pollock P, Abel PD 2010 Osteoporos is in patients with prostate canceronlong-term androgen deprivation therapy: an increasing but under-recognised problem. BJU Int 106:726-727; author reply 727